Evidence map›Paper›PMID 33842201›Full record

ArticlePreventive medicine reports2021

Primary nonadherence to statin medications: Survey of patient perspectives.

Derjung M Tarn, Mark J Pletcher, Rosa Tosqui, Alicia Fernandez, Chi-Hong Tseng, Rachel Moriconi, Douglas S Bell, Maureen Barrientos, Jon A Turner, Janice B Schwartz

Open access · goldAbstract read
In one paragraph

Article in Preventive medicine reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
5.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Not obtaining a medication the first time it is prescribed: primary non-adherence to cardiovascular pharmacotherapy.Clinical research in cardiology : official journal of the German Cardiac Society · 2024
    Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Derjung M TarnDepartment of Family Medicine, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, CA, USA.
Mark J PletcherDepartment of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA.
Rosa TosquiDepartment of Family Medicine, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, CA, USA.
Alicia FernandezDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Chi-Hong TsengDivision of General Internal Medicine and Health Services Research, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, CA, USA.
Rachel MoriconiDepartment of Family Medicine, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, CA, USA.
Douglas S BellDivision of General Internal Medicine and Health Services Research, David Geffen School of Medicine at UCLA, University of California, Los Angeles, Los Angeles, CA, USA.
Maureen BarrientosDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Jon A TurnerDepartment of Technology, Operations, and Statistics, Stern School of Business, New York University, New York, NY, USA.
Janice B SchwartzDepartment of Medicine, University of California, San Francisco, San Francisco, CA, USA.
University of California, Los Angeles · USUniversity of California, San Francisco · USNew York University · US

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
Clinical and Translational Science InstituteUL1TR001872 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI COLLARD, HAROLD R, JACOBY, VANESSA · 2016 to 2025
$112.1M
Mentoring in the Context of Improving Care for Latinos with DiabetesK24DK102057 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERNANDEZ, ALICIA · 2014 to 2018
$919k
Patient perspectives on primary statin nonadherenceR21AG055832 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TARN, DERJUNG M · 2017 to 2018
$378k
NCATS NIH HHS UL1 TR001872NCATS NIH HHS UL1 TR001881NIA NIH HHS R21 AG055832NIDDK NIH HHS K24 DK102057
6 · The paper itself

Abstract

Statin medications reduce cardiovascular events, but many patients never start taking their prescribed statin (primary nonadherence). Limited knowledge exists about the attitudes and beliefs of those with primary nonadherence. In this study, patients with primary nonadherence to statin medications (n = 173) completed a self-administered cross-sectional survey that assessed their attitudes and beliefs related to primary nonadherence and to potential motivators for statin use. Patients were recruited in 2019 from two academic health systems and nationwide internet advertisements. Only 49 of 173 (28.3%) patients with primary nonadherence reported having cardiovascular disease (CVD). Ninety-nine patients (57.2%) never filled their prescription, and 74 (42.8%) filled but never took any statin. Over half failed to initially inform their prescriber they might not take the statin. Patients strongly or somewhat agreed that they desired alternate treatment plans such as diet and/or exercise (n = 134; 77.4%) or natural remedies/dietary supplements (n = 125; 72.3%). Ninety-eight (56.6%) stronglyor somewhat worried about the possibility of statin dependence or addiction. Twenty-seven (15.6%) patients noted that they would not take a statin based solely on CVD risk estimates; 50 (28.9%) selected a CVD risk threshold of >20%; and 23 (13.3%) a threshold of >50% as motivating factors to take statins. Patients with primary nonadherence have attitudes about taking statins based on CVD risk that differ from scientific recommendations, may not tell providers about their hesitation to take statins, and likely prefer alternative initial approaches to cholesterol lowering. Early shared decision-making and assessment of patient attitudes about statins could potentially better align initial approaches for CVD risk reduction.

Indexed as

Medication adherencePrimary nonadherenceStatinsSurveys and questionnaires

Identifiers

PMID33842201
PMCPMC8020471
OpenAlexW3136835093

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.